Canada · Delayed Price · Currency is CAD Intercept Pharmaceuticals Statistics
Total Valuation
CSE:NUKE has a market cap or net worth of CAD 24.49 million. The enterprise value is 24.51 million.
| Market Cap | 24.49M |
| Enterprise Value | 24.51M |
Important Dates
The last earnings date was Friday, August 1, 2025.
| Earnings Date | Aug 1, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CSE:NUKE has 46.20 million shares outstanding. The number of shares has increased by 47.44% in one year.
| Current Share Class | 46.20M |
| Shares Outstanding | 46.20M |
| Shares Change (YoY) | +47.44% |
| Shares Change (QoQ) | +19.98% |
| Owned by Insiders (%) | 10.50% |
| Owned by Institutions (%) | n/a |
| Float | 41.35M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 37.57 |
| P/TBV Ratio | 37.57 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -34.05 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -29.05 |
Financial Position
The company has a current ratio of 0.58, with a Debt / Equity ratio of 0.06.
| Current Ratio | 0.58 |
| Quick Ratio | 0.18 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.05 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -166.06% and return on invested capital (ROIC) is -90.24%.
| Return on Equity (ROE) | -166.06% |
| Return on Assets (ROA) | -77.38% |
| Return on Invested Capital (ROIC) | -90.24% |
| Return on Capital Employed (ROCE) | -101.96% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | n/a |
| Average Volume (20 Days) | 9,673 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -664,560 |
| Pretax Income | -719,786 |
| Net Income | -719,786 |
| EBITDA | n/a |
| EBIT | -664,560 |
| Earnings Per Share (EPS) | -0.03 |
Balance Sheet
The company has 20,707 in cash and 40,000 in debt, giving a net cash position of -19,293 or -0.00 per share.
| Cash & Cash Equivalents | 20,707 |
| Total Debt | 40,000 |
| Net Cash | -19,293 |
| Net Cash Per Share | -0.00 |
| Equity (Book Value) | 651,787 |
| Book Value Per Share | 0.02 |
| Working Capital | -48,034 |
Cash Flow
In the last 12 months, operating cash flow was -337,634 and capital expenditures -505,945, giving a free cash flow of -843,579.
| Operating Cash Flow | -337,634 |
| Capital Expenditures | -505,945 |
| Free Cash Flow | -843,579 |
| FCF Per Share | -0.02 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CSE:NUKE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -47.44% |
| Shareholder Yield | n/a |
| Earnings Yield | -2.94% |
| FCF Yield | -3.45% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |